Sionna Therapeutics, Inc. (SION) company profile
Close on Nov 17, 2026Market cap $138.80MP/E –Yield –
About Sionna Therapeutics
Pharmaceutical Preparations, SIC 2834
This clinical-stage biopharmaceutical company discovers and develops small-molecule therapeutics to treat cystic fibrosis by restoring CFTR protein function. Its pipeline centers on nucleotide binding domain 1 (NBD1) stabilizers, notably lead candidates SION-719 and SION-451, designed to correct defects caused by the F508del genetic mutation. The company also advances complementary CFTR modulators, including transmembrane domain 1 correctors such as SION-2222 and SION-2851, the intracellular loop 4 corrector SION-109, and the potentiator SION-3067. Its product candidates are designed either to be administered alongside the existing standard of care or paired into proprietary dual-combination therapies. The company targets people living with cystic fibrosis, particularly individuals carrying the F508del mutation.
The company operates as a clinical-stage entity without disclosing commercial offices, physical facilities, or operational territories in the excerpt. Its clinical development activities encompass Phase 1 and Phase 2a clinical trials evaluating healthy adult participants and cystic fibrosis patients. The provided text does not state the location of the company's headquarters.
Summary of the business section of Sionna Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Sionna Therapeutics, Inc.
- Headquarters
- Waltham, MA
- Address
- 21 Hickory Drive, Suite 500 02451
- Phone
- (617) 819-2020
- Website
- sionnatx.com
- Employees
- 59, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte& Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- SION
- Exchange
- Nasdaq
- IPO date
- Feb 7, 2025
- Shares outstanding
- 45M, Jul 31, 2026
- Public float
- $342.01M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2036042
- CUSIP
- 829401108
- ISIN
- US8294011080
- FIGI
- BBG016X2DC85
- Share class FIGI
- BBG016X2DCF7
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael Cloonan | President & CEO, Director | 765,393 |
| Charlotte McKee | CMO and Head of R&D | 78,415 |
| Elena Ridloff | CFO and CBO | 85,801 |
| Jennifer Fitzpatrick | CLO and Head of Program Mgmt. | 28,133 |
| Caroline Stark Beer | Chief Business Officer | – |
| Ra Capital Management, L.P. | Director | 3,448,812 |
| Capital Healthcare Fund LP RA | Director | – |
| Rajeev M. Shah | Director | – |
| RA Capital Nexus Fund III, L.P. | Director | 715,988 |
| Peter Kolchinsky | Director | 2,198,082 |
| RA Capital Nexus Fund, L.P. | Director | – |
| Capital GP VIII LLC OrbiMed | Director | 2,469,959 |
| Peter A. Thompson | Director | 2,469,959 |
| Advisors Llc Orbimed | Director | 2,555,877 |
| Harold Edward Fleming | Director | – |
| Joanne L. Viney | Director | – |
| Marcella K. Ruddy | Director | – |
| Paul J. Clancy | Director | – |
| Bruce Booth | Director | 3,057,453 |
| Laurie Stelzer | Director | – |
| Joshua Resnick | Director | – |
| Lucian Iancovici | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Michael Cloonan President and Chief Executive Officer | $646.58K | – | $5.95M | $374.06K | $10.00K | $6.98M | +87% |
| Elena Ridloff Chief Financial Officer | $506.68K | – | $2.09M | $254.93K | $10.00K | $2.86M | +120% |
| Caroline Stark Beer Chief Business Officer | $158.95K | $30.00K | $5.32M | $71.60K | $7.57K | $5.59M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 7, 2025
- Offer price
- $18.00
- Securities offered
- 10,588,233
- Gross proceeds
- $190.59M
- Exchange
- Nasdaq
- First trading day
- Feb 7, 2025
- First-day close
- $25.00+38.9%
- Lock-up ends (est.)
- Aug 6, 2025
“The initial public offering price per share is $18.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 15, 2026, we had 59 full-time employees, of which 15 had M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 7, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 4, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?